Background The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) …

Background There is a paucity of data on COVID-19 vaccines in people living with HIV-1,
who could be at increased risk of severe illness and death from COVID-19. We evaluated the …

COVID-19 vaccine efficacy (VE) has been observed to vary against antigenically distinct
SARS-CoV-2 variants of concern (VoC). Here we report the final analysis of VE and safety from …

Background: Accurate self-report of sexual behavior assists in identifying potential HIV
exposure in HIV prevention trials. Brief mobile phone assessments, completed daily or after …

In this South African phase 1/2b study, we demonstrated vaccine efficacy (VE) of two doses
of AZD1222 for asymptomatic and symptomatic SARS-CoV-2 infection: 90.6% against wild-…

In this South African phase 1/2b study, we demonstrated vaccine efficacy (VE) of two doses
of AZD1222 for asymptomatic and symptomatic SARS-CoV-2 infection 90.6% against wild-…

Introduction Malawi is rapidly closing the gap in achieving the UNAIDS 95‐95‐95 targets,
with 90% of people living with HIV in Malawi aware of their status. As we approach epidemic …

2.1 Background The OCIS team’s overarching goal is the accelerated development of a long-acting
(up to 90 days) IVR delivering a broad-spectrum antiviral peptide and a small-…

Background Malawi is rapidly closing the gap in achieving the UNAIDS 95-95-95 targets,
with 90% of people living with HIV in Malawi aware of their status. As we approach epidemic …

The emergence of SARS-CoV-2 Variants of Concern (VOCs) with mutations in key neutralizing
antibody epitopes threatens to undermine vaccines developed against the pandemic …